Diffuse Large B Cell Lymphoma  >>  hydrocortisone  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
hydrocortisone / Generic mfg.
NCT00482053: Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Terminated
2
3
US
Autologous hematopoietic stem cell transplantation (auto-HSCT), Autologous peripheral blood progenitor cell (PBPC) transplantation, Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Allogeneic peripheral blood progenitor cell (PBPC) transplantation, Total lymphoid irradiation (TLI), Rituximab, Rituxan, Mabthera, Carmustine, BCNU, BiCNU, Etoposide, Eposin, Etopophos, Vepesid, VP-16, Filgrastim, Granulocyte colony-stimulating factor (G-CSF, GCSF), Colony-stimulating factor 3 (CSF-3), Anti-thymocyte globulin (ATG), Cyclosporine, Cyclosporin, CSP, Mycophenolate mofetil (MMF), CellCept, Cyclophosphamide, Cytoxan, Neosar, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Hydrocortisone, Cortef, Methylprednisolone, Solu-Medrol
Stanford University
Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
05/10
05/10
2014-003031-19: This is a study to valuate the activity and feasibility of a new sequential chemoimmunotherapy program in patients with Diffuse Large B Cell Lymphoma and central nervous system involvement at diagnosis or relapse.

Ongoing
2
76
Europe
METROTREXATO, RITUXIMAB, CITARABINA, IFOSFAMIDE, CARBOPLATINO, ETOPOSIDE, TIOTEPA, BCNU, cytarabine liposome intrathecal, Solution for injection, Concentrate for solution for infusion, Injection, Solution for infusion, Powder for solution for injection, Powder for concentrate for solution for infusion, Powder for solution for infusion, Suspension for injection, methotrexate, Cytarabine, rituximab, Etoposide, carboplastin, hydrocortisone
IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP), International Extranodal Lymphoma Study Group, IELSG, Erasmus MC, NKI-AVL, LUMC
systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse, systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02329080: New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Active, not recruiting
2
76
Europe, RoW
Methotrexate, Rituximab, Cytarabine, Thiotepa, liposomial cytarabine, Etoposide, Ifosfamide, Carmustine, whole brain radiotherapy
International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B-cell Lymphoma
08/19
12/23
NCT04479267: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Recruiting
2
49
US
Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione, 53-03-2, Adasone, Cortancyl, Dacortin, , Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, 1,2-Dehydrohydrocortisone, 50-24-8, 9120, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Methylprednisolone, (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione, 6Alpha-Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Rituximab, 174722-31-7, 687451, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, POLATUZUMAB VEDOTIN, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Cyclophosphamide, 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Doxorubicin Hydrochloride, 14-Hydroxydaunorubicin Hydrochloride, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma
11/25
11/26

Download Options